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Abstract A three-dimensional structure of Schistosoma ansoni cathepsin B was modelled using the coordinates ofthe crystal structure of the human 
liver enzyme. Both enzymes appear to share remarkable structural similarity. However, an examination of the models complexed with two synthetic 
inhibitors revealed ifferences in inhibitor binding, as confirmed by differences in the 50% inhibitory concentration of the same inhibitor. 
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1. Introduction 
Cathepsin B, a widely studied cysteine proteinase, is known 
to function in the degradation of tissue proteins [1]. It has also 
been implicated in a number of pathological conditions uch as 
tumour metastasis [2] and dystrophy [3], as well as in the proc- 
essing of protein precursors [4]. The molecular structure of the 
human liver cathepsin B has been determined by X-ray analysis 
at 2.15 /k resolution [5]. The deduced amino acid sequence 
corresponding to a Schistosoma mansoni protein of 31 kDa 
(termed Sm31) exhibits nearly 70% homology to cathepsin B 
from human liver [6]. Taking advantage of the sequence similar- 
ity, a 3-dimensional model was constructed. The schistosome 
proteinase is believed to be one of several digestive nzymes [7] 
and thus, may be of  critical importance to the life cycle of the 
parasite. Therefore, we analyzed more closely the structure of 
the two cathepsins for a better understanding of enzyme-inhib- 
itor interactions, in order to aid in the design of parasite-spe- 
cific inhibitors as novel chemotherapeutic agents. 
2. Materials and methods 
Determination of inhibitory activities. The inhibitors used were 
a peptidyldiazomethane (Z-Trp-MetCHN2) [8] and a E-64 deriva- 
tive, compound N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-isoleucyl-L- 
proline (CA-074) [9]. The latter was a kind gift of Taisho Pharmaceuti- 
cal Co. Ltd., Japan. The inhibitory activities are shown as their 50% 
inhibitory concentrations (IC50), as carried out by Murata et al [9]. 
Activity was assayed at pH 6.0 using benzyloxycarbonyl-phenylalanyl- 
arginyl-7-amino-4-methylcoumarin (Z-Phe-Arg-AMC) as a substrate 
(5 gM final concentration) and Sm31 or human liver cathepsin B (150 
pM final concentration), asdescribed by Barrett and Kirschke [1]. Each 
IC50 value is the mean of at least three experiments. Km values as 
calculated under our assay conditions with Sm31 and human liver 
cathepsin B are 33.0 + 7.1 (S.D.) pM and 112 + 39 (S.D.)pM, respec- 
tively. 
Tertiary structure modelling. The structure of the schistosome Sm31 
protease was modelled directly from the coordinates of the human 
cathepsin B enzyme [5]. Appropriate amino-acid replacements, inser- 
tions and deletions were performed using the programs Biopolymer and 
Builder (Biosym Technologies) followed by successive stages of energy- 
minimization, using the conjugate gradients method and the CVFF 
*Corresponding author. 
forcefield of the program Discover (Biosym Technologies). The final 
minimization was to 0.01 kcalL~ maximum derivative. 
The binding of the diazomethane inhibitor Z-Trp-MetCHN2 [8] to 
the two proteases was modelled by copying the Z-Phe-methylenyl-Ala 
inhibitor from the structure of papain [10] of the 6PAD entry in the 
Protein Data Bank at Brookhaven National Laboratory [11,12] to the 
human or schistosome protease. The inhibitor was then converted to 
Z-Trp-MetCHN2 as above with energy-minimization of the inhibitor 
portion at each step. Finally the inhibitor and all atoms within 10 A of 
the inhibitor, including a 5/k water layer, were energy-minimized to a 
final maximum derivative of 0.01 kcal//k. The CA-074 inhibitor [9] was 
'grown' stepwise onto Cys 29 of each protein again minimizing the en- 
ergy of the inhibitor portion at each stage. A final energy-minimization 
step was performed as for the diazomethane inhibitor. 
3. Results and discussion 
Fig. 1 shows an alignment of the amino acids of cathepsin 
B from the human liver and from Schistosoma mansoni. 148 of 
the 252 amino acids are identical, while an additional 25 are 
conservative changes. The numbering of amino acids follows 
that introduced for human cathepsin B [5]. Thus Met 66 of the 
human enzyme (shown as superscript) is deleted in the schis- 
tosome and a lysine (shown as subscript and numbered 124 A 
in Fig. 1) is inserted between positions 124 and 125. Both 
changes occur on the surface of the molecule. Even though it 
is difficult to predict the exact conformation due to the change, 
we can assume that the insertion has little or no effect on the 
binding site. In the human, the dipeptide Ala48-His 49 is excised 
during processing of the enzyme to yield one light and one 
heavy chain. In agreement with the fact that a double-chain 
form has never been detected in the schistosome [13], we find 
two amino acids, Gly and Lys, at positions 48 and 49, respec- 
tively. Furthermore, the last two C-terminal amino acids of the 
human enzyme are absent in the schistosome enzyme, for which 
there is no evidence of carboxyterminal processing, and termi- 
nation of the protein is characterized by an authentic stop 
codon in the cDNA [6]. The overall result of the amino acid 
substitutions is an increase in the net charge from -3  in the 
human enzyme to +12 in the schistosome. These new positive 
charges appear to be fairly randomly distributed throughout 
the molecule, but with a particular concentration i one section 
corresponding to residues 122-137. 
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Fig. 1. Comparison of the Sm31 protease from Sch~tosoma mansoni 
and human liver cathepsin B. Errors in the deduced amino acid se- 
quence of Sm31 as published in [6] are corrected here. + and - under- 
neath the alignment indicate where an amino acid change causes a
charge difference. All His residues are considered asprotonated atthe 
physiological pH 5. 
The 2.15 A crystal structure of the human enzyme reveals a 
30 A thick disc-shaped molecule, the diameter of which is 50 
,~. In between the left-hand and right-hand omains, on top of 
the molecule is a V-shaped incision where the active-site cleft 
is found. In the center of the cleft is the active Cys 29 and the 
rear of the cleft is closed by a loop of peptide containing two 
His residues (110 and 111). Because of the extensive sequence 
identities, we were able to model the entire molecule using the 
X-ray coordinates of the human enzyme. Fig. 2 shows a back- 
bone trace stereo diagram of the schistosome enzyme. Like the 
crystalline human cathepsin B, the main features are three hel- 
ical segments and the 'occluding' loop in the L-domain, and six 
extended strands forming an open barrel-like structure in the 
R-domain. Residues 122-137 where many of the new positively 
charged residues are concentrated, corespond to an external 
loop on the protein surface originating in the left rim of the 
binding cleft. There are no changes in the positions of the 
cysteines in the sequence, so it is expected that the six disulphide 
pairs in both molecules are the same. Thus, there are no signif- 
icant changes in the model structure of the schistosome cathep- 
sin B compared with the crystal structure of the human pro- 
teinase. The structural imposition of the schistosome and 
human enzymes is shown in Fig. 3. 
Since we were interested in using the model to make predic- 
tions about peptide inhibitors, we first focussed our attention 
on comparing amino acids comprising the active sites. One part 
of the left-hand side of the active site cleft is formed by the 
segment CysII9-Glu122. A Lys at 122 in the schistosome instead 
of Glu makes this part positively charged. The amino acids 
contributing to the rest of the left rim Gly24-Trp 3° and Asn 72- 
Tyr 75 are fairly conserved with respect o the human enzyme. 
Noteworthy are three further changes, namely that of Gly 24 to 
Ser, Ser 25 to Arg and Asn 72 to Glu. Overall, the presence of Lys 
and Arg renders this region more hydrophilic than the human 
counterpart. Next, we examined how inhibitors interacted by 
modelling the synthetic diazomethane inhibitor Z-Trp- 
MetCHN 2 into the active sites of the two enzymes (Fig. 4A,B). 
The amino acid residues of the inhibitor Met and Trp are found 
on the S1 and $2 subsites, respectively. The P1 Met residue was 
observed to project out of the cleft in the general direction of 
Glu ~22 in the human enzyme, and appears to occupy the same 
position in the schistosome enzyme, even though Glu ~22 is re- 
placed by Lys. 
The right-hand side of the cleft is formed by Phe~8°-Leu Is2
and Metl96-His 199. While the change from Leu ~82 to Asn creates 
a more hydrophilic environment in the schistosome, the Met 196 
to Leu change makes no significant contribution. The amino 
acids forming the floor of the cleft are Trp TM, Gln 23, His 199, 
Ala 2°°, Ala j73 and Cys 29, all of which are conserved, except for 
a change from Ala 173 to Ser, which represents part of the base- 
ment of the $2 depression. Consequently, the region is more 
hydrophilic due to the presence of the hydroxyl group in Ser. 
In fact, this part of the cleft appears wider, where Ile replaces 
Tyr 75 and Ser replaces mla 173. Hence, the P2 Trp residue of the 
inhibitor lies sideways in the cleft and is able to form a hydro- 
gen bond between the indole N of the Trp and the OH of Set t73. 
Such a bond is likely to contribute to the stability of the en- 
zyme-inhibitor interaction (Fig. 4A). On the other hand, the 
cleft of the human enzyme is comparatively narrow with the 
Trp residue being sandwiched vertically between Tyr 75 on the 
left rim and Ala 173 and Ala 2°° on the floor (Fig. 4B). Experimen- 
tally, Z-Trp-MetCHN 2was found to exhibit stronger inhibitory 
activity for the schistosome enzyme (IC50 value of 2 + 0.2 nM) 
than for the human enzyme (33 + 6 nM). 
1 12 Lys 111 His 1 12~ Lys / - -~ .~ 111 His 
Fig. 2. A backbone trace stereo diagram of S. mansoni Sm31 polypeptide chain. Some of the amino acids residues are given to assist in the orientation 
of the molecule, which follows that shown for human cathepsin B [5]. The active site cleft (V-shaped) ison 'top' of the molecule and the 'occluding 
loop' at His H° and His H' is 'behind' the active site. The L and R domains are on the left- and right-hand side, respectively. Disulfide connections 
are as observed in the human enzyme and are indicated by lines drawn perpendicularly to the main strand. 
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Fig. 3. Carbon atom structure of schistosome Sm31 (in heavier lines) superimposed with human cathepsin B. The view is identical to that in Fig. 2. 
The second inhibitor CA-074 was observed to occupy a dif- 
ferent position in the active site cleft in the human enzyme, such 
that the amino acid residues of the inhibitor Ile and Pro are 
found in the SI' and $2' positions, respectively (D. Turk, pers. 
comm.). Thus, the PI '  side chain of lie projects towards the 
right rim and is surrounded by the side chains of His 199, Leu ~8~, 
Leu 196 and Trp TM, while the P2' side chain of Pro points towards 
the left rim (Fig. 4C). The schistosome cleft appears to be 
narrow, probably caused by the change in the side chain posi- 
tions from Asn 72 to Glu and from Met 196 to Leu. Thus the 
inhibitor appears to be more constricted and lies extended 
along the floor and towards the back of the cleft. In compari- 
son, CA-074 in the human enzyme is found in a wider cleft than 
in the schistosome enzyme and contact surface area between 
inhibitor and human enzyme is greater, thus probably assisting 
its binding (Fig. 4D). This could be a possible xplanation as 
to why CA-074 is more inhibitory for the human enzyme (IC50 
of 0.43 + 0.11 nM) than the schistosome nzyme (2.3 + 
0.6 nM). 
The present report has outlined the remarkable overall simi- 
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Fig. 4. Models of inhibitors at the active site clefts. Inhibitor molecules are shown in heavier lines. (A and C) Schistosome Sm31 and (B and D) human 
cathepsin B are complexed with Z-Trp-MetCHN 2and CA-074, respectively. Differences inbinding of inhibitors to the two enzymes are discussed 
in the text. 
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larity between the human and the schistosome cathepsin B, in 
terms of both primary and three-dimensional structures. Con- 
flicting with this finding is the detection of a strong and very 
early immune response against he parasite nzyme in S. man- 
soni-infected humans [14]. A possible explanation for this ob- 
servation is the involvement of regions of considerable differ- 
ence, such as the external loop of residue 122-137, but it could 
also be due to the lysosomal confinement of the human enzyme 
as opposed to the location of parasite cathepsin B in the intes- 
tinal lumen of schistosomes, uch that it is continuously regur- 
gitated into the host bloodstream. 
In spite of their overall similarities, we have shown that the 
active sites of the two proteins present distinct differences. We 
have also proposed that these structural differences may ac- 
count for the experimentally observed ivergence in susceptibil- 
ity to protease inhibitors. Further combined crystallographic 
and biochemical studies will be useful in the design of parasite- 
specific inhibitors and possibly in the elucidation of its role(s) 
in the schistosome. 
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